Learning outcomes
By the end of this lesson you should be able to: assess pain with an appropriate tool, including in the child, the cognitively impaired and the critically ill; construct a multimodal analgesic plan for postoperative pain using the ladder; convert and titrate opioid doses safely with equianalgesic tables; state the maximum daily doses of paracetamol and ibuprofen and the risks of the non-steroidal anti-inflammatory drugs; manage opioid side effects and treat opioid toxicity with naloxone; and outline the pathway for chronic neuropathic pain and for acute-on-chronic pain.
Prerequisites
Lesson 2 (Applied anaesthetic pharmacology) — opioid pharmacology and naloxone — and the physiology of nociception: transduction, transmission, modulation and perception, with the sympathetic and amplification of the dorsal-horn reflex.
The big idea
Unrelieved acute pain has consequences that go far beyond discomfort: it causes tachycardia and hypertension, immobilisation and deep-vein thrombosis, splinting and atelectasis, aortic catecholamine surge, a hypercoagulable state, nausea and vomiting, chronic sensitisation of the spinal cord (converting acute to chronic pain), and delirium. The phrase to structure a plan around is 'treat before the pain becomes uncontrolled' — giving a non-opioid regularly rather than an opioid 'as required', because a request for rescue opioid is a signal the plan failed. Pre-emptive and regular non-opiotic dosing, regional blocks, and a written, stepwise plan are the architecture of acute pain management.
Assessing pain
| Tool | For whom | How it is used |
|---|---|---|
| Numerical rating scale 0–10 | Adults who can self-report | 0 = no pain, 10 = worst imaginable; record at rest and on movement (on coughing, on mobilising) because movement pain predicts function |
| Visual analogue scale | Adults and adolescents | A 100 mm line anchored by 'no pain' and 'worst pain' |
| Wong-Baker faces or Oucher | Children over about 3 years | Six faces from smiling to crying, chosen by the child |
| FLACC | Pre-verbal children and children who cannot self-report | Face, Legs, Activity, Cry and Consolability, each scored 0–2 |
| PAINAD | Patients with dementia or delirium | Observing Breathing, Negative vocalisation, Facial expression, Body language and Consolability |
| Behavioural Pain Scale | Mechanically ventilated or sedated intensive-care patients | Facial expression, upper-limb movements and compliance with ventilation, each scored 1–4 |
Watch outChronic opioid use, dementia, delirium and sedation all blunt the behavioural signs of pain, so a quiet, grimacing patient is not necessarily comfortable. In sedation scores, always pair behavioural scoring with an analgesic trial (a small opioid bolus) and re-score, and remember that analgesia is a separate axis from sedation in critical care.
The analgesic ladder and the multimodal plan
The 1986 World Health Organization ladder was designed for cancer pain and has three steps: paracetamol or a non-steroidal anti-inflammatory drug (with or without an adjuvant) for mild pain; a weak opioid added for moderate pain; a strong opioid for severe pain. Modern acute postoperative practice has simplified and improved on it by giving the non-opioid step 1 and 2 drugs together from the start, adding regional anaesthesia, and reserving opioids for breakthrough pain — better called 'opioid-sparing' rather than 'opioid-free'.
| Class and drug | Dose | Mechanism | Principal risks and cautions |
|---|---|---|---|
| Paracetamol | 1 g every 6 hours, maximum 4 g/day (reduce to 3 g/day in low body weight, malnutrition, age over 75, or hepatic or renal impairment) | Central action — COX inhibition and descending serotonergic pathways | Hepatotoxicity in overdose, and drug accumulation and cumulative harms with combination products; take the whole day's dose from all sources into account |
| Non-steroidal anti-inflammatory drug: ibuprofen, diclofenac, naproxen | Ibuprofen 400 mg three times daily; diclofenac 50 mg three times daily; naproxen 500 mg twice daily | COX-1 and COX-2 inhibition, reducing prostaglandin-mediated peripheral sensitisation | Gastric ulceration, renal impairment (avoid if estimated glomerular filtration rate is below 30–45 or with hypovolaemia), bronchospasm in aspirin-sensitive asthma, and impaired bone healing; give the shortest effective course, with a proton-pump inhibitor in higher-risk patients |
| Weak opioid: codeine, tramadol, dihydrocodeine | Codeine 30–60 mg every 4 hours (maximum 240 mg/day); tramadol 50–100 mg every 4–6 hours (maximum 300 mg/day over 75 years) | Codeine is 10% morphine after CYP2D6 conversion, hence the 'variable and unpredictable' effect; tramadol inhibits noradrenaline and serotonin reuptake as well as mu receptors | Codeine causes constipation with no advantage over a small morphine dose; tramadol causes serotonin syndrome (avoid with selective serotonin reuptake inhibitors) and seizures in overdose; both have a short effective duration |
| Strong opioid: morphine (oral, immediate release or modified release), oxycodone, fentanyl | Oral morphine 5–10 mg every 4 hours as an immediate-release starting dose; intravenous morphine 0.05–0.1 mg/kg titrated in 1–2 mg increments | Mu-receptor agonism in the dorsal horn, brainstem and cortex | Respiratory depression, sedation, nausea, constipation, urinary retention, pruritus, tolerance, dependence and (uncommonly) addiction; see conversion below |
| Adjuvants: gabapentinoids, amitriptyline, capsaicin, ketamine | Gabapentin 100–300 mg at night, titrated to 300 mg three times daily in the postoperative setting; amitriptyline 10–25 mg at night for neuropathic pain | Gabapentinoids bind the alpha-2-delta subunit of the calcium channel in the dorsal horn; amitriptyline blocks noradrenaline and serotonin reuptake | Sedation, dizziness, weight gain; renal dose adjustment for gabapentin; in major surgery the combination of gabapentinoids and opioids increases sedation and respiratory depression, so titrate |
NoteOpioids work better as a rescue than as a backbone. Giving regular paracetamol and a non-steroidal anti-inflammatory drug, and local anaesthetic infiltration or a regional block, reduces 24-hour opioid consumption by 30–50% in major surgery, and with it nausea, vomiting, ileus and sedation. The one situation in which opioids are given early and liberally is uncontrolled pain — and even then the first question is whether the underlying cause (a distended bladder, compartment syndrome, an ischaemic limb, an undiagnosed fracture) has been missed.
Opioid conversion and titration
| Conversion | Rule | Caveat |
|---|---|---|
| Oral morphine to subcutaneous or intravenous morphine | Divide by 3 (oral bioavailability about 30%) | Titrate downwards if the patient is frail, elderly or renally impaired; incomplete cross-tolerance requires a 25–50% dose reduction when switching |
| Oral morphine to codeine | Codeine is roughly one-tenth as potent | Codeine's effect is genetically variable (CYP2D6 poor and ultra-rapid metabolisers), so a fixed conversion is a poor substitute for titration |
| Oral morphine to a transdermal fentanyl patch | Roughly 25 micrograms/h per 60 mg per day of oral morphine | The patch takes 12–24 hours to reach a steady state, so give residual morphine when starting; a patch is never used for unstable or acute pain |
| Morphine to oxycodone | Oral morphine 10 mg is approximately equivalent to oxycodone 5 mg (a factor of about 2) | Monitor for oxycodone accumulation in renal impairment |
| Titration in the acute setting | Titrate 1–2 mg intravenous morphine every 5–10 minutes until the pain is controlled | Continuous pulse oximetry is not mandatory but respiratory rate and sedation are; prescribers must be confident in managing opioid overdose |
Watch outConverting from one opioid to another is never 1:1. Incomplete cross-tolerance means the starting dose should be 50% of the calculated equivalent, then titrated, particularly when changing to methadone, fentanyl or transdermal preparations. The commonest cause of opioid-related death in community and palliative prescribing is a conversion error combined with breakthrough doses added on top.
Opioid side effects, toxicity and addiction
Prescribe the side-effect management at the same time as the opioid, not after the complication: a laxative (stimulant plus softener: senna, docusate, macrogol) for constipation, which is the one effect that never shows tolerance; an anti-emetic (a dopamine antagonist such as ondansetron, or cyclizine, or low-dose naloxone in resistant pruritus after discussion) for nausea; and a bowel-versus-bladder review for urinary retention. Toxicity is recognised by the grading of sedation — a patient who is 'sleepy but rousable' has already passed the safe window, and 'only rousable to pain' is an emergency.
| Clinical state | Signs | Action |
|---|---|---|
| Effective analgesia | Pain controlled, alert or normally sleepy, respiratory rate over 10, saturation in target | Continue and reassess; the plan is working |
| Excessive sedation | Difficult to rouse, reduced respiratory rate under 8, pin-point pupils | Stop any further opioid, call an anaesthetist, oxygen, stimulate, prepare naloxone; document the neurological observation |
| Opioid overdose | Respiratory rate under 8 or apnoea, unresponsive pupils, hypoxia, bradycardia | Assist ventilation with bag-mask and oxygen immediately; titrate naloxone in 100 micrograms increments intravenously (400 micrograms if respiratory arrest), or a 2 mg intranasal or intramuscular dose; observe for 30 minutes for re-narcotisation |
| Chronic use and dependence | Tolerance (increasing dose for the same effect), physical dependence (withdrawal on stopping) and opioid-induced hyperalgesia | Plan weaning and a multidisciplinary approach; distinguish from addiction, which is a separate behavioural disorder involving loss of control and compulsive use |
NoteTake-home naloxone is standard practice for patients on long-term opioids with risk factors (a history of overdose, respiratory disease, concurrent benzodiazepines). Its use with family members is part of the consent conversation, and its education is a legal duty in many countries.
Anaesthetic and regional contributions
| Technique | Indication | Notes and complications |
|---|---|---|
| Local infiltration and wound catheters | Most surgical wounds | Local anaesthetic into the wound at the end of surgery, or a catheter for continuous infusion; inexpensive and safe |
| Peripheral nerve block | Limb surgery, abdominal wall, thoracotomy, caesarean section | Ultrasound-guided with a nerve stimulator as backup; gives complete analgesia of the operative area for hours to days; complications are inadvertent intravascular injection, nerve injury and LAST |
| Neuraxial: epidural and spinal | Major abdominal, thoracic and orthopaedic surgery, labour, fractured neck of femur | A continuous epidural covers a segmental distribution and enables mobilisation and physiotherapy; hypotension is handled by fluid and vasopressors, and a postoperative epidural requires monitoring of motor and sensory level |
| Ketamine at subanaesthetic doses | Opioid-resistant pain and severe chronic pain; acute-on-chronic in the opioid-tolerant patient | 0.1–0.3 mg/kg repeated, or an infusion; avoid in hypertension, ischaemic heart disease and psychosis; psychomimetic at higher doses |
| Patient-controlled analgesia (PCA) | Postoperative pain, sickle cell crisis, burns and palliative care | A demand dose with a lockout interval (morphine 1 mg with a 5-minute lockout is a common adult prescription) with a 4-hour limit; safe because the patient is the control, but avoid in confusion, respiratory failure and inability to understand the device |
Chronic pain
Chronic pain — pain persisting beyond three months or beyond expected healing — is managed by a biopsychosocial pathway, not a linear ladder, because persistent pain involves central sensitisation, fear-avoidance beliefs, sleep disturbance and mood. The mainstays are: for neuropathic pain, amitriptyline (10–25 mg at night, titrated to 75 mg) or duloxetine, and a gabapentinoid (gabapentin or pregabalin) as second line, with a capsaicin cream for localised peripheral neuropathic pain; for musculoskeletal pain, structured exercise, weight management, cognitive behavioural therapy and a pain-management programme, with non-steroidal anti-inflammatory drugs in short courses and topical agents first; and for intractable cancer pain, the World Health Organization ladder with a strong opioid, adjuvant analgesics, and interventional procedures (nerve blocks, coeliac plexus block, intrathecal therapy) around the breakthrough symptom. The distinction between opioid dependence, which is expected after prolonged use, and addiction, which is a behavioural disorder, remains central to the ethics and the safety of prescribing.
A 68-year-old woman has had a knee replacement and is prescribed paracetamol 1 g four times daily, ibuprofen 400 mg three times daily and oxycodone 10 mg modified release twice daily, with oxycodone 5 mg required for breakthrough. She is opioid-naive. What is the problem and the fix?
Common mistakes
Watch outPrescribing an opioid 'as required' only. An as-required request is a symptom of uncontrolled pain, and a patient who cannot press the call bell, or who is asleep when the rounds come, receives no analgesia at all.
Watch outAdding codeine to paracetamol tablets to make a 'stronger' analgesic. Codeine's variable and unpredictable metabolism, a distinct lack of efficacy in trials, and its constipation make it a poor choice compared with a titrated morphine dose.
Watch outPrescribing a non-steroidal anti-inflammatory drug in a patient with a reduced glomerular filtration rate, hypovolaemia, a peptic-ulcer history or aspirin-sensitive asthma. Check renal function and the bleeding history, avoid where the estimated glomerular filtration rate is below 45 mL/min or the patient is dehydrated, and use the shortest effective course with a proton-pump inhibitor if the risk is high.
Watch outFailing to prescribe a laxative with a new strong opioid, or failing to diagnose a complication that is presenting as pain — a distended bladder, compartment syndrome, an ischaemic limb, an anastomotic leak or a surgical wound haematoma.
Watch outTitrating a modified-release opioid in an opioid-naive patient, or converting from another opioid at a 1:1 ratio. Modified-release preparations are for stable pain only, and every conversion has a 25–50% reduction for incomplete cross-tolerance.
Check your understanding
Why is a multimodal plan more effective than the sum of its parts rather than simply better tolerated?
List the paracetamol and ibuprofen maximum daily doses for a 70 kg adult, and the dose adjustments for the frail elderly.
How would you manage a patient who is on morphine 30 mg twice daily and develops breakthrough pain after abdominal surgery that you assess as moderate?
Multiple choice
Which statement about codeine is correct?
A postoperative patient on fentanyl has a respiratory rate of 6 and is unrousable with pin-point pupils. What is the immediate management?
Which analgesic has a ceiling that makes a combination of paracetamol and ibuprofen additive but not indefinitely dose-titratable upwards?
A patient requires oral morphine to codeine conversion. What is the approximate relationship?
Which patient is at greatest risk of harm from a paracetamol-containing combination product?
Summary and next
Pain is assessed with a scale appropriate to the patient, treated regularly rather than as required, and delivered by the multimodal route: paracetamol (maximum 4 g/day, 3 g/day in the frail), a short course of a non-steroidal anti-inflammatory drug where the kidneys and stomach allow, a regional or local block wherever the surgery allows it, and opioids titrated to effect with a rescue dose about one-tenth of the total daily morphine dose and a written plan for its side effects. Toxicity is managed by ventilation and titrated naloxone, not by full reversal; chronic pain takes a biopsychosocial pathway with gabapentinoids, amitriptyline and pain programmes.
Next: pre-operative evaluation and monitoring. Before any of the analgesia, fluids or drugs of the previous lessons can be given safely, the patient must be assessed, optimised and consented — and the monitoring that keeps them safe has to be in place from induction to recovery.